Editorial Comments

1 The Relation between Renin-Angiotensin-Aldosterone System Blockade and Contrast-Induced Nephropathy: An Unresolved Issue
Balta, S. (Eskişehir); Aparci, M. (Ankara)

25 Renoprevention Revisited – The Impact of Preemptive Withdrawal of RAAS Blockade prior to Iodinated Contrast Exposure in Older CKD Patients: Results of a New Meta-Analysis
Onuigbo, M.A.C. (Eau Claire, Wis.)

34 Percutaneous Pericardiocentesis: Safety First!
Lazaros, G. (Athens); Imazio, M. (Turin); Tousoulis, D. (Athens)

Original Research

4 The Impact of Renin-Angiotensin-Aldosterone System Blockade on Contrast-Induced Nephropathy: A Meta-Analysis of 12 Studies with 4,493 Patients
Jo, S.-H. (Anyang-si); Lee, J.M.; Park, J.; Kim, H.-S. (Seoul)

17 Predictive Value of Endostatin in Chronic Heart Failure Patients with Poor Kidney Function
Ueland, T.; Aukrust, P.; Nymo, S.H.; Kjekshus, J. (Oslo); McMurray, J.J.V. (Glasgow); Wikström, J. (Goteborg); Wienhues-Thelen, U.-H.; Block, D. (Penzberg); Zaugg, C. (Rotkreuz); Gullestad, L. (Oslo)

27 Effect of Autologous Bone Marrow Cell Transplantation Combined with Off-Pump Coronary Artery Bypass Grafting on Cardiac Function in Patients with Chronic Myocardial Infarction

37 Pericardiocentesis Adverse Event Risk Factors: A Nationwide Population-Based Cohort Study
Ho, M.-Y. (Linkou); Wang, J.-L. (Pingzhen City); Lin, Y.-S. (Chaiyi); Mao, C.-T. (Keelung); Tsai, M.-L.; Wen, M.-S.; Wang, C.-C.; Hsieh, I.-C.; Hung, K.-C.; Wang, C.-Y. (Linkou); Wu, H.-P. (Keelung); Chen, T.-H. (Linkou/Taoyuan/Xiamen)

55 Oxidized Low-Density Lipoprotein Promotes Osteoblastic Differentiation of Valvular Interstitial Cells through RAGE/MAPK
Li, F. (Wuhan); Zhao, Z. (Ezhou); Cai, Z. (Hangzhou); Dong, N.; Liu, Y. (Wuhan)

62 Transforming Cardiovascular Disease Prevention in Women: Time for the Pygmalion Construct to End
Wenger, N.K. (Atlanta, Ga.)

Novel Insights from Clinical Experience

48 Dilated, Arrhythmogenic Cardiomyopathy in Emery-Dreifuss Muscular Dystrophy Due to the Emerin Splice-Site Mutation c.449 + 1G>A
Finsterer, J.; Stöllberger, C.; Seshal, E.; Rehder, H.; Laccone, F. (Vienna)

(Continued on inside front cover)
Letters to the Editor

Suciu, Z.; Benedek, T.; Benedek, I. (Targu Mures)

23 Red Cell Distribution Width: A Predictor of All-Cause Mortality in Patients with Coronary Artery Disease
Balta, S. (Eskişehir); Aparci, M.; Ozturk, C.; Demirkol, S.; Celik, T. (Ankara)

46 The Effect of Age on Right Ventricular Diastolic Function Parameters
Demirkol, S.; Ozturk, C.; Aparci, M. (Ankara); Balta, S. (Eskişehir); Unlu, M.; Iyisoy, A. (Ankara)

47 Response to the Paper by Demirkol et al. Entitled ‘The Effect of Age on Right Ventricular Diastolic Function Parameters’

52 The Effect of Metformin on Cardiac Fibrosis via Differentiation of Cardiac Fibroblasts
Ünlü, M. (Ankara); Balta, Ş. (Eskişehir); Arslan, Z.; Öztürk, C.; Celik, T.; Iyisoy, A. (Ankara)

54 Response to the Paper by Ünlü et al. Entitled ‘The Effect of Metformin on Cardiac Fibrosis via Differentiation of Cardiac Fibroblasts’
Li, J.; Song, S. (Baoding)
CARDIOLOGY

International Journal of Cardiovascular Medicine, Surgery, Pathology and Pharmacology


Incorporating Heart Drug (published 2001–2005)

Editor-in-Chief

Jeffrey S. Borer, New York, N.Y.

Associate Editors

D. Atar, Oslo
H. Boudouhas, Athens
J.A. Franciosa, New York, N.Y.
I.J. Gelb, Boca Raton, Fla.
X. Huang, Boca Raton, Fla.
J.T. Kassotis, Brooklyn, N.Y.
B.S. Lewis, Haifa
A.B. Miller, Jacksonville, Fla.
D.J. Sahn, Portland, Oreg.
A. Salemi, New York, N.Y.
S. Sasayama, Kyoto
J. Somberg, Chicago, Ill.
H. Taegtmeyer, Houston, Tex.

Editorial Board

E. Abadie, Saint Denis
D.H. Adams, New York, N.Y.
C.W. Akins, Boston, Mass.
J.S. Alpert, Tucson, Ariz.
E.A. Amsterdam, Davis, Calif.
W.S. Aronow, Valhalla, N.Y.
J.J. Badimon, New York, N.Y.
J. Bax, Leiden
R.C. Becker, Durham, N.C.
G.A. Beller, Charlottesvile, Va.
P.C. Block, Atlanta, Ga.
R.O. Bonow, Chicago, Ill.
A.S. Budziskowski, Brooklyn, N.Y.
A.J. Camm, London
B.A. Carabello, Houston, Tex.
K. Chatterjee, Iowa City, I.A.
P.F. Cohn, Stony Brook, N.Y.
J. Coromillas, New Brunswick, N.J.
M.H. Crawford, San Francisco, Calif.
J.E. Dalen, Tucson, Ariz.
S. Dalla Volta, Padova
P.C. Deedwania, Fresno, Calif.
A.N. De Maria, San Diego, Calif.

J.A. Elefteriades, New Haven, Conn.
U. Elkayam, Los Angeles, Calif.
C. Erol, Ankara
M.D. Ezekowitz, Wynnewood, Pa.
R. Ferrari, Ferrara
G. Filippatos, Athens
G.I. Fishman, New York, N.Y.
K. Fox, London
G.W. Francis, Minneapolis, Minn.
V. Fuster, New York, N.Y.
B.J. Gersh, Rochester, Minn.
W. Gersony, New York, N.Y.
J.P. Gold, Toledo, Ohio
M.E. Goldman, New York, N.Y.
P.J. Goldschmidt, Miami, Fla.
J.L. Halperin, New York, N.Y.
Z.-X. He, Beijing
D. Heistad, Iowa City, Iowa
E.M. Herrold, Brooklyn, N.Y.
G. Heusch, Essen
C.A. Hochreiter, New York, N.Y.

(Continued on next page)
<table>
<thead>
<tr>
<th>Name</th>
<th>City, State/Province</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. Hori</td>
<td>Osaka</td>
</tr>
<tr>
<td>S.K.S. Huang</td>
<td>Temple, Tex.</td>
</tr>
<tr>
<td>B.K. Kantharia</td>
<td>Houston, Tex.</td>
</tr>
<tr>
<td>J.S. Karliner</td>
<td>San Francisco, Calif.</td>
</tr>
<tr>
<td>R.E. Kerber</td>
<td>Iowa City, Iowa</td>
</tr>
<tr>
<td>N.Z. Kerin</td>
<td>Detroit, Mich.</td>
</tr>
<tr>
<td>A. Kimchi</td>
<td>Los Angeles, Calif.</td>
</tr>
<tr>
<td>R.N. Kligfield</td>
<td>New York, N.Y.</td>
</tr>
<tr>
<td>X. Kong</td>
<td>Nanjing</td>
</tr>
<tr>
<td>M.A. Konstam</td>
<td>Boston, Mass.</td>
</tr>
<tr>
<td>J.B. Kostis</td>
<td>New Brunswick, N.J.</td>
</tr>
<tr>
<td>P. Kowey</td>
<td>Wynnewood, Pa.</td>
</tr>
<tr>
<td>K.H. Krieger</td>
<td>New York, N.Y.</td>
</tr>
<tr>
<td>H. Krum</td>
<td>Melbourne, Vic.</td>
</tr>
<tr>
<td>E. Kuschnir</td>
<td>Córdoba</td>
</tr>
<tr>
<td>H. Kusuoka</td>
<td>Osaka</td>
</tr>
<tr>
<td>W. Laskey</td>
<td>Albuquerque, N. Mex.</td>
</tr>
<tr>
<td>J.M. Lazar</td>
<td>Brooklyn, N.Y.</td>
</tr>
<tr>
<td>C.V. Leier</td>
<td>Columbus, Ohio</td>
</tr>
<tr>
<td>M.C. Limacher</td>
<td>Gainesville, Fla.</td>
</tr>
<tr>
<td>R.J. Lipicky</td>
<td>North Potomac, Md.</td>
</tr>
<tr>
<td>T.F. Lüscher</td>
<td>Zurich</td>
</tr>
<tr>
<td>F.I. Marcus</td>
<td>Tuscon, Ariz.</td>
</tr>
<tr>
<td>A.J. Marian</td>
<td>Houston, Tex.</td>
</tr>
<tr>
<td>J.D. Marmur</td>
<td>Brooklyn, N.Y.</td>
</tr>
<tr>
<td>F.A. Martinez</td>
<td>Córdoba</td>
</tr>
<tr>
<td>M.G. Massad</td>
<td>Chicago, Ill.</td>
</tr>
<tr>
<td>P. Meier</td>
<td>London</td>
</tr>
<tr>
<td>E.H. Messerli</td>
<td>New York, N.Y.</td>
</tr>
<tr>
<td>J. Midwall</td>
<td>Atlantis, Fla.</td>
</tr>
<tr>
<td>R.M. Mills</td>
<td>Raritan, N.J.</td>
</tr>
<tr>
<td>J.E. Mitchell</td>
<td>Brooklyn, N.Y.</td>
</tr>
<tr>
<td>R.J. Myerburg</td>
<td>Miami, Fla.</td>
</tr>
<tr>
<td>J. Narula</td>
<td>Orange, Calif.</td>
</tr>
<tr>
<td>J.V. Nixon</td>
<td>Richmond, Va.</td>
</tr>
<tr>
<td>H. Oh</td>
<td>Okayama</td>
</tr>
<tr>
<td>P. Pibarot</td>
<td>Quebec City, Que.</td>
</tr>
<tr>
<td>B. Pitt</td>
<td>Ann Arbor, Mich.</td>
</tr>
<tr>
<td>G.M. Pohost</td>
<td>Los Angeles, Calif.</td>
</tr>
<tr>
<td>E.N. Prystowsky</td>
<td>Indianapolis, Ind.</td>
</tr>
<tr>
<td>N. Reichek</td>
<td>Roslyn, N.Y.</td>
</tr>
<tr>
<td>W.J. Remme</td>
<td>Rhoon</td>
</tr>
<tr>
<td>R. Roberts</td>
<td>Ottawa, Ont.</td>
</tr>
<tr>
<td>W.C. Roberts</td>
<td>Dallas, Tex.</td>
</tr>
<tr>
<td>R. Rosenhek</td>
<td>Vienna</td>
</tr>
<tr>
<td>F. Ruschitzka</td>
<td>Zurich</td>
</tr>
<tr>
<td>J.N. Ruskin</td>
<td>Boston, Mass.</td>
</tr>
<tr>
<td>M.E. Sarano</td>
<td>Rochester, Minn.</td>
</tr>
<tr>
<td>V.L. Serebruany</td>
<td>West Friendship, Md.</td>
</tr>
<tr>
<td>M.R. Starling</td>
<td>Mesa, Ariz.</td>
</tr>
<tr>
<td>P. Supino</td>
<td>Brooklyn, N.Y.</td>
</tr>
<tr>
<td>J.L. Swain</td>
<td>La Jolla, Calif.</td>
</tr>
<tr>
<td>K. Swedberg</td>
<td>Göteborg</td>
</tr>
<tr>
<td>A.J. Tajik</td>
<td>Rochester, Minn.</td>
</tr>
<tr>
<td>L. Tavazzi</td>
<td>Cotignola</td>
</tr>
<tr>
<td>J.R. Teerlink</td>
<td>San Francisco, Calif.</td>
</tr>
<tr>
<td>M. Tendara</td>
<td>Katowice</td>
</tr>
<tr>
<td>U. Thadani</td>
<td>Oklahoma City, Okla.</td>
</tr>
<tr>
<td>K. Thygesen</td>
<td>Aarhus</td>
</tr>
<tr>
<td>N.K. Wenger</td>
<td>Atlanta, Ga.</td>
</tr>
<tr>
<td>W.B. White</td>
<td>Farmington, Conn.</td>
</tr>
<tr>
<td>J.T. Willerson</td>
<td>Houston, Tex.</td>
</tr>
<tr>
<td>R.G. Williams</td>
<td>Los Angeles, Calif.</td>
</tr>
<tr>
<td>K.K.-Y. Wu</td>
<td>Zhunan Town</td>
</tr>
<tr>
<td>F. Zannad</td>
<td>Nancy</td>
</tr>
<tr>
<td>B.L. Zaret</td>
<td>New Haven, Conn.</td>
</tr>
<tr>
<td>D.P. Zipes</td>
<td>Indianapolis, Ind.</td>
</tr>
</tbody>
</table>
Submission
Cardiology publishes original reports in cardiovascular physiology, pathophysiology, disease and therapy. Only original papers written in English are considered. The manuscripts should be submitted using the online submission website:

www.karger.com/crd

If you have any problems with submission, please contact:
S. Karger AG
Editorial Office ‘Cardiology’
P.O. Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1356
Fax +41 61 306 1434
E-Mail crd@karger.com

All manuscripts must be accompanied by a covering letter signed by all authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication and that there are no conflicts of interest, see below. The preferred word processing package is Word for Windows®. Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see N Engl J Med 1997;336:309–315).

Main Sections
1. Original Research
2. Original Research – Clinical Trial Design
Submissions will be accepted reporting the study design protocols of planned clinical trials that have been appropriately registered with regulatory authorities. These submissions will be limited to 4500 words and 35 references.

3. Review
4. Turning Basic Research into Clinical Success
One or two focused review articles are published in each issue, and should offer an overview of existing concepts and literature in a format assimilable to the largely clinical cardiologist readership, i.e. a reader-friendly base with limited sophistication as to methods and terminology associated with cell and molecular biology. Most manuscripts are submitted upon invitation. Authors planning to submit an unsolicited paper are requested to contact the Editorial Office with an outline of the intended contribution. Contributions to this section are expected to provide novel insights into a clinical problem. Submissions can be based on a single case or a number of similar cases. While a case report can describe an entirely novel clinical condition, it is unlikely that most case reports will provide such information. In the more common setting of a description of a well-recognized condition, the most important aspect of the presentation, on which editorial judgments will be based, is the description of the new perspective(s) on the phenotype, pathophysiology, clinical presentation, evaluation strategy and/or management that can be drawn from the case(s).

5. Letter to the Editor
Letters to the Editor (max. 1,500 words, including references) are encouraged if they directly concern articles previously published in this journal and issues raised by those articles. The Editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal.

6. Novel Insights from Clinical Experience (formerly Case Reports)
Contributions to this section are expected to provide novel insight into a clinical problem. Submissions can be based on a single case or a number of similar cases. While a case report can describe an entirely novel clinical condition, it is unlikely that most case reports will provide such information. In the more common setting of a description of a well-recognized condition, the most important aspect of the presentation, on which editorial judgments will be based, is the description of the new perspective(s) on the phenotype, pathophysiology, clinical presentation, evaluation strategy and/or management that can be drawn from the case(s).

7. Short Communications
These manuscripts should not contain more than 2,000 words, including key words, essential references (not more than 15) and no more than 3 tables or figures. Such communications should represent complete, original studies and should be arranged in the same way as full length manuscripts.

8. Commentary
Authors who wish to contribute a manuscript to this category should contact the Editor. Commentaries should offer a more personalized perspective on a topic that will be of interest to the general readership. All contributions are subject to peer review by members of our editorial board. All contributions to this category will be subject to editorial review for relevance to the readership, perception of topicality and general importance/interest, and quality of the submitted work. To submit a Letter to the Editor, see point 5 above.

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Cardiology and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflict of Interest in Cardiovascular Publications
Declaration of potential conflict of interest should be part of each publication or presentation and be designated as one of four categories: (1) No relationship. (2) Relationship with a For Profit Organization. (3) Research relationship with a For Profit or Not For Profit Organization, which should be named. (4) Employee of a For Profit or Not For Profit Organization. For legal reasons, all authors are required to sign a Copyright Transfer & Conflicts of Interest Statement. The corresponding author must ensure that all authors have been asked to sign this form and to disclose any conflicts of interest.

Ethics
Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute’s committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Plagiarism
Authors should not appropriate the ideas, language or other elements of the work of others without providing appropriate attribution (i.e., ‘plagiarism’). Plagiarism includes, but is not limited to, verbatim copying without quotation marks, close paraphrasing or summarization of sentences or narrative passages without citing source, and duplication of figures, graphs, images or data without acknowledgement of their origins. Authors also should not submit a previously published manuscript or a section of a previously published manuscript, even when re-titled, otherwise re-worded or augmented, without clearly identifying its relation to the author’s earlier work (duplicate publication or ‘self-plagiarism’). For additional guidance, see Roig, M.: Plagiarism and self-plagiarism: What every author should know. Biochimia Medica 2010:20:295–300.

Arrangement
Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as a running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

For submissions to Main Sections 1, 2 and 3:
Original Research, Original Research – Clinical Trial Design, and Review Papers
Abstract: The abstract is an essential and must read part of the paper. It should be printed on a separate page, up to 200 words, factual, free of abbreviations (except as specifically defined within the abstract text at first use) and should be structured as follows: Objectives: Should describe the purpose of the study addressing the problem addressed, should include at least one sentence providing the rationale or justification for the study. Methods: Should explain how the study was performed (samples and/or population, procedures, analytical methods). Results: Should describe the main findings with specific data and their statistical significance, if possible. Conclusions: Should contain a succinct interpretation of the inferences to be drawn from results.
Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figures a legend, also prepared on a separate sheet. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author's name. b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions at http://www.karger.com/crd/).

Color illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.00 per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they appear. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples

(b) Papers published only with DOI numbers: Theodorides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.


Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet publication quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author’s Choice
With this option the author can choose to make his article freely available online against a one-time fee of CHF 3,000.00. This fee is independent of any standard charges for supplementary pages, color images etc. which may apply. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy are available at http://publicaccess.nih.gov/FAQ.htm#a1

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger's Author's Choice feature, however, are also permitted to archive the final, published version of their article, which includes copypasting and design improvements as well as citation links.

Page Charges
There are no page charges for papers of 6 or fewer print pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approx. 18 manuscript pages (including tables, illustrations and references).

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
### Advances in Cardiology

**Well-documented scientific studies to aid progress in the management of cardiac disease**

This series is devoted to current problems in clinical and preventive cardiology. Edited or authored by renowned specialists, volumes in this series are designed to provide up-to-date and comprehensive coverage of a particular subject. Some volumes record the proceedings of important symposia. Special emphasis is given to new findings relating to diagnostic and therapeutic measures, cardiac pharmacology, and drug-disease interactions, and to the fundamental cellular and molecular pathophysiology underlying cardiovascular disease processes. Areas of interest range throughout the field of cardiology to include coronary artery disease, congenital and acquired valvular and other structural heart diseases, primary myocardial diseases and primary and secondary electrophysiologic dysfunction.

### Vol. 47: Antiplatelet Therapy in ACS and A-Fib

**Editors:** Serebruany, V.L. (Towson, Md.); Atar, D. (Oslo)

- **XVI + 170 p., 20 fig., 6 in color, 2012**
- **CHF 142.00 / EUR 118.00 / USD 167.00**
- **e-ISSN 1662–2839**
- **ISSN 0065–2326**

### Vol. 46: Obstructive Sleep Apnea in Adults – Relationship with Cardiovascular and Metabolic Disorders

**Author:** Lune, A. (Paris)

- **XVI + 272 p., 95 fig. in color, 37 tab., 2011**
- **CHF 160.00 / EUR 139.00 / USD 196.00**
- **(hard cover)**
- **CHF 200.00 / EUR 170.00 / USD 235.00**
- **(online)**

### Vol. 45: Cardiovascular Diabetology: Clinical, Metabolic and Inflammatory Facets

**Editors:** Serebruany, V.L. (Towson, Md.); Atar, D. (Oslo)

- **XVI + 310 p., 80 fig., 67 in color, 2010**
- **CHF 180.00 / EUR 150.00 / USD 212.00**
- **(hard cover)**
- **CHF 216.00 / EUR 180.00 / USD 254.00**
- **(online)**

### Vol. 44: Atherosclerosis, Large Arteries and Cardiovascular Risk

**Editors:** Safar, M.E. (Paris); Frohlich, E.D. (New Orleans, La.)

- **XVI + 244 p., 65 fig., 1 in color, 29 tab., 2007**
- **CHF 216.00 / EUR 180.00 / USD 254.00**
- **(hard cover)**
- **CHF 259.00 / EUR 216.00 / USD 305.00**
- **(online)**

### Progress in Respiratory Research

**Presents and interprets new data on all aspects of the respiratory system in health and disease**

Important aspects of the respiratory system, from its role in the alimentation and protection of the organism to its susceptibility to disease, receive attention in the volumes published in this series. Some volumes present debates on topics vital to respiratory research. Others represent the unique experiences of a single renowned author and stand as first-time treatments of specific issues. ‘The blue series’ is designed for researchers as well as clinicians and extends to them a collection of valuable reference tools.

### Vol. 41: Pulmonary Vascular Disorders

**Editors:** Humbert, M. (Clamart); Souza, R. (São Paulo); Simonneau, G. (Clamart)

- **X + 290 p., 82 fig., 21 in color, 45 tab., 2012**
- **CHF 212.00 / EUR 170.00 / USD 249.00**
- **(hard cover)**
- **CHF 254.00 / EUR 212.00 / USD 299.00**
- **(online)**

### Vol. 40: Anti tuberculosis Chemotherapy

**Editors:** Donald, P.R.; van Helden, P.D. (Tygerberg)

- **X + 252 p., 53 fig., 2 in color, 2011**
- **CHF 168.00 / EUR 157.00 / USD 221.00**
- **(hard cover)**
- **CHF 226.00 / EUR 188.00 / USD 265.00**
- **(online)**

### Vol. 39: New Drugs and Targets for Asthma and COPD

**Editors:** Hansel, T.T.; Barnes, P.J. (London)

- **XIV + 310 p., 80 fig., 67 in color, 46 tab., 2010**
- **CHF 248.00 / EUR 207.00 / USD 292.00**
- **(hard cover)**
- **CHF 296.00 / EUR 248.00 / USD 350.00**
- **(online)**

### Vol. 38: Paediatric Bronchoscopy

**Editors:** Peiris, K.N. (Athens); Anthracopoulos, M.B. (Patras); Eber, E. (Graz); Koumourlis, A.C. (Washington, D.C.); Wood, R.E. (Cincinnati, Ohio)

- **X + 212 p., 116 fig., 87 in color, 37 tab., and online supplementary material, 2010**
- **CHF 188.00 / EUR 157.00 / USD 221.00**
- **(hard cover)**
- **CHF 226.00 / EUR 188.00 / USD 265.00**
- **(online)**

---

**Downloaded by:** 54.191.40.80 - 9/17/2017 4:14:33 AM
Contents

See the journal website for contents
The Forum will take place at the Amora Jamison Hotel in Sydney, Australia, 8th-9th May 2015. Register before the Festive Season to secure your place.

KEY NOTE SPEAKERS INCLUDE:

- Professor Bertram Pitt: University of Michigan School of Medicine
- Professor Orson Moe: University of Texas Southwestern Medical Center
- Professor Xueqing Yu: The First Affiliated Hospital of Sun Yat-sen University

For full registration and program details please visit www.cardiorenal.com.au

FOR FURTHER INFORMATION
Please contact Drew Whait on +61 2 9265 0764 or email dwhait@arinex.com.au
CONGRESS ORGANISED BY THE HEART FAILURE ASSOCIATION OF THE ESC

HEART FAILURE
23-26 MAY
SEVILLE
2015
SPAIN

Get ready to submit your abstract
14 November 2014 to 14 January 2015

4 days of scientific exchange
+2 000m² of exhibition
+100 scientific sessions including sessions dedicated to the 2nd World Congress on Acute Heart Failure
+300 international expert faculty members
4 500 healthcare professionals from 70+ countries
+1 500 abstracts and clinical cases
+20 industry sessions (satellite, hands-on sessions...)

www.escardio.org/HFA

HEART FAILURE TAKING CENTRE STAGE: DRUGS, DEVICES AND MULTIDISCIPLINARY CARE

2nd WORLD CONGRESS ON ACUTE HEART FAILURE 2015
ESC CONGRESS
LONDON 2015
29 August – 2 September
Where cardiology comes together

IMPORTANT DATES
Mid Dec - 14 Feb   Abstract submission
Mid Jan - 1 March  Clinical case submission
Mid March - 1 May  Hot Lines submission
31 May           Early Registration deadline
31 July           Late Registration deadline

5 days of scientific Sessions  150 CV Topics  30 000 healthcare professionals from 140 countries
10 000 abstracts submitted  500 expert sessions  180 exhibiting companies
& all year long on ESC Congress 365

www.escardio.org/ESC2015
Seize the opportunity to showcase your scientific achievements and educational material to an international audience: submit your abstracts for CIRSE 2015!

SUBMIT YOUR ABSTRACTS by February 26, 2015
The Journal of Vascular Research publishes original articles and reviews of scientific excellence in vascular and microvascular biology, physiology and pathophysiology. The scope of the journal covers a broad spectrum of vascular and lymphatic research, including vascular structure, vascular function, haemodynamics, mechanics, cell signalling, intercellular communication, growth and differentiation. JVR’s ‘Vascular update’ series regularly presents state of the art reviews on hot topics in vascular biology. Manuscript processing times are, consistent with stringent review, kept as short as possible due to electronic submission. All articles are published online first, ensuring rapid publication. The Journal of Vascular Research is the official journal of the European Society of Microcirculation.

A biennial prize is awarded to the authors of the best paper published in the journal over the previous two years, thus encouraging young scientists working in the exciting field of vascular biology to publish their findings.

Journal of Vascular Research

Founded: 1964
Category: Basic Research
Field of Interest: Cardiovascular System

Listed in bibliographic services, including Current Contents®/Life Sciences, Pubmed/MEDLINE, Biological Abstracts, Excerpta Medica

2015: Volume 52
6 issues per volume
Language: English
ISSN 1018–1172
e-ISSN 1423–0135

Impact Factor: 2.443

More information at www.karger.com/jvr
An expertly written, practical handbook for the clinical assessment and management of children with inherited and acquired bleeding and clotting disorders

SickKids Handbook of Pediatric Thrombosis and Hemostasis

Editors
Victor S. Blanchette
Vicky R. Breakey
Shoshana Revel-Vilk

This handbook takes the reader through the entire field of pediatric thrombosis and hemostasis. An introductory section concisely explains the complex pathophysiology of hemostasis and thrombosis. The chapters that follow include practical, evidence-based information on the diagnosis and management of inherited and acquired bleeding disorders and thrombotic events of the venous, arterial, cardiac and central nervous systems that affect children. Special features include practical clinical algorithms and appendices that cite normal laboratory reference ranges, as well as recommended dosages of blood products and major hemostatic agents. A stand-alone chapter is dedicated to developmental hemostasis and bleeding in the neonate. A chapter on antithrombotic therapy in children gives succinct information on the old and new anticoagulants, antiplatelet drugs and thrombolytic agents.

Written and reviewed by international experts in the field, this handbook is intended for health care professionals involved in the assessment and care of children with inherited and acquired bleeding and clotting disorders, including general and specialist pediatricians (in particular intensivists, neonatologists, cardiologists/cardiac surgeons, rheumatologists and nephrologists), hematologists/oncologists (pediatric and adult), as well as medical trainees, nurses, nurse practitioners and pharmacists.

Contents

• Contributors
• Preface
• Pediatric Thrombosis and Hemostasis: A Historical Perspective: Breakey, V.R.; Blanchette, V.S.
• Primary and Secondary Hemostasis, Regulators of Coagulation, and Fibrinolysis: Understanding the Basics: Revel-Vilk, S.; Rand, M.L.; Israels, S.J.
• An Approach to the Bleeding Child: Revel-Vilk, S.; Rand, M.L.; Israels, S.J.
• Bleeding in the Neonate: Avila, L.; Barnard, D.
• Platelet Disorders in Children: van Eimeren, V.; Kahr, W.H.A.
• Managing Hemophilia in Children and Adolescents: Robertson, J.D.; Curtin, J.A.; Blanchette, V.S.
• von Willebrand Disease in Children: Breakey, V.R.; Carcao, M.
• Rare Congenital Factor Deficiencies in Childhood: Xavier, F.; Blanchette, V.S.
• Acquired Bleeding Disorders in Children: Kumar, R.; Steele, M.
• A Diagnostic Approach to a Child with Thrombosis: Rizzi, M.; Barnes, C.
• Venous Thrombosis: Price, V.E.; Brandão, L.R.; Williams, S.
• Arterial Thrombosis: Revel-Vilk, S.; Albisetti, M.; Massicotte, M.P.
• Thromboembolic Events at Specific Organ Sites: Labarque, V.; Chan, A.K.C.; Williams, S.
• Pediatric Stroke: Andrade, A.; Ichord, R.; Dlamini, N.; Williams, S.; deVeber, G.
• Bleeding and Clotting in Children with Cardiac Disease: Diab, Y.; McCrindle, B.W.; Brandão, L.R.
• Antithrombotic Therapy in Children: Biss, T.; Monagle, P.
• Appendix I: Reference Ranges for Common Tests of Bleeding and Clotting: Breakey, V.R.
• Appendix II: Common Products Used to Manage Bleeding and Clotting: Simpson, E.; Liebman, M.

The easiest way to order: www.karger.com/sickkids

Karger – Medical and Scientific Publishers
CH–4009 Basel, Switzerland
orders@karger.com, f +41 61 306 12 34
www.karger.com
A new approach to treating AYA with hematological malignancies

Adolescents and Young Adults with Hematological Disorders
Challenges and Perspectives

Editors
Martin S. Tallman
Pia Raanani

The distinct biology of haematological disorders as well as other age-related issues in adolescent and young adult (AYA) patients deserves unique psychological and medical attention. It emphasizes the necessity for a treatment approach taking into consideration their special needs. These include fertility considerations, survivorship issues, psychological support, adherence to treatment difficulties and other dilemmas and problems exclusive to this group of patients. AYA patients may usually better support intensive treatments and if possible should be referred to special centres and participate in clinical trials. In recent years the focus on AYA patients in oncology and hemato-oncology has increased. Still a distinct approach to these patients is an unmet need.

This special issue tries to increase awareness for this group of patients as well as to cover the wider spectrum of hematological disorders that is pertinent to AYA patients who face special therapeutic challenges. This publication is of interest for physicians dealing with AYA, especially in the field of hematology and oncology, as well as for medical staff including nurses, psychologists, social workers and pharmacists.

Contents
• The Challenges and Perspectives in Treating Adolescent and Young Adult Patients with Hematological Disorders: Raanani, P.; Tallman, M.S.
• Acute Lymphoblastic Leukemia in Adolescents and Young Adults: Burke, P.W.; Douer, D.
• The Challenging Aspects of Managing Adolescents and Young Adults with Hodgkin’s Lymphoma: Jachimowicz, R.D.; Engert, A.
• Acute Myeloid Leukemia in Adolescents and Young Adults: Ofri, Y.; Rowe, J.M.
• Chronic Myeloid Leukemia in Adolescents and Young Adults: Patient Characteristics, Outcomes and Review of the Literature: Pemmaraju, N.; Cortes, J.
• Acute Promyelocytic Leukemia in Children and Adolescents: Stein, E.M.; Tallman, M.S.
• Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults: Tewari, P.; Franklin, A.R.; Tarek, N.; Askins, M.A.; Mofield, S.; Kebril, E.P.
• Challenging Aspects of Managing Hemostasis in Adolescents: Nowak-Göttl, U.; Kenet, G.
• Adherence-Related Issues in Adolescents and Young Adults with Hematological Disorders: Leader, A.; Raanani, P.
• Nursing Care for Adolescents and Young Adults with Cancer: Literature Review: Dreyer, J.; Schwartz-Attias, I.
• Peer and Romantic Relationships among Adolescent and Young Adult Survivors of Childhood Hematological Cancer: A Review of Challenges and Positive Outcomes: Foster, R.H.; Stern, M.
• Survivorship in Adolescents and Young Adults: Kishtagar, A.; Tavakkoli, M.; Park, J.H.
• Cardiotoxicity and Cardioprotection in Childhood Cancer: Lipshultz, S.E.; Sambatakos, P.; Maguire, M.; Karnik, R.; Ross, S.W.; Franco, V.J.; Miller, T.L.
• Fertility Preservation in Young Females with Hematological Malignancies: Shapira, M.; Raanani, H.; Cohen, Y.; Meirov, D.
• Challenges for Cancer Care Delivery to Adolescents and Young Adults: Present and Future: Meenaghan, M.R.; Wood, W.A.

Author Index / Subject Index

The easiest way to order: www.karger.com/aha

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f: +41 61 306 12 34
www.karger.com

Orders may be placed with any bookseller, subscription agency, directly with the publisher or through a Karger distributor.

Dear Librarian
I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

The easiest way to order: www.karger.com/aha

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f: +41 61 306 12 34
www.karger.com

Orders may be placed with any bookseller, subscription agency, directly with the publisher or through a Karger distributor.

Dear Librarian
I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

The easiest way to order: www.karger.com/aha

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f: +41 61 306 12 34
www.karger.com

Orders may be placed with any bookseller, subscription agency, directly with the publisher or through a Karger distributor.
Most endocrine diseases, if not treated or controlled, have cardiovascular manifestations. Both GH deficiency and GH excess impair cardiovascular functions, e.g. in patients with acromegaly, who have a shortened life expectancy and increased mortality mostly due to cardiovascular complications in uncontrolled disease. Moreover, Cushing’s syndrome and diabetes are well known for metabolic and cardiovascular manifestations, as well as hypop- and hyperthyroidism. Both adipose tissue and the heart have been increasingly recognized as organs with partially endocrine functions, which produce adipokines and brain natriuretic peptide, respectively, and influence a number of cardiovascular parameters. Primary aldosteronism as a cause for secondary hypertension is still a great challenge to detect and diagnose properly; however, new important discoveries have been made regarding the genetics of this probably underestimated cause of hypertension. Written by distinguished researchers in their respective fields, this book will give both researchers and clinicians an excellent update on all these topics, as well as provide insight into the use of hormones as treatment tools in more controversial areas.